Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018, Article ID 2180373, 16 pages
https://doi.org/10.1155/2018/2180373
Review Article

Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome

1Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
2Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania
3Stefan S. Nicolau Institute of Virology, Molecular Virology Department, 030304 Bucharest, Romania
4Titu Maiorescu University, Faculty of Medicine, 040441 Bucharest, Romania

Correspondence should be addressed to Simona Mihai; moc.liamg@12iahim.anomis

Received 13 June 2018; Accepted 8 August 2018; Published 6 September 2018

Academic Editor: Donato Zipeto

Copyright © 2018 Simona Mihai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Dregan, J. Charlton, P. Chowienczyk, and M. C. Gulliford, “Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study,” Circulation, vol. 130, no. 10, pp. 837–844, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Guarner and M. E. Rubio-Ruiz, “Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease,” Interdisciplinary Topics in Gerontology, vol. 40, pp. 99–106, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Pawelec, D. Goldeck, and E. Derhovanessian, “Inflammation, ageing and chronic disease,” Current Opinion in Immunology, vol. 29, pp. 23–28, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. P. F. Todendi, L. G. Possuelo, E. I. Klinger et al., “Low-grade inflammation markers in children and adolescents: influence of anthropometric characteristics and CRP and IL6 polymorphisms,” Cytokine, vol. 88, pp. 177–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Minihane, S. Vinoy, W. R. Russell et al., “Low-grade inflammation, diet composition and health: current research evidence and its translation,” British Journal of Nutrition, vol. 114, no. 7, pp. 999–1012, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. B. Salgado-Bernabé, L. E. Ramos-Arellanol, I. P. Guzmán-Guzmán et al., “Significant associations between C-reactive protein levels, body adiposity distribution and peripheral blood cells in school-age children,” Investigacion Clinica, vol. 57, no. 2, pp. 120–130, 2016. View at Google Scholar
  7. R. A. Bawaked, H. Schröder, L. Ribas-Barba et al., “Association of diet quality with dietary inflammatory potential in youth,” Food & Nutrition Research, vol. 61, no. 1, article 1328961, 2017. View at Publisher · View at Google Scholar
  8. R. B. Oriá, L. E. Murray-Kolb, R. J. Scharf et al., “Early-life enteric infections: relation between chronic systemic inflammation and poor cognition in children,” Nutrition Reviews, vol. 74, no. 6, pp. 374–386, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Hänsel, S. Hong, R. J. A. Cámara, and R. von Känel, “Inflammation as a psychophysiological biomarker in chronic psychosocial stress,” Neuroscience & Biobehavioral Reviews, vol. 35, no. 1, pp. 115–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Sharma, S. Agrawal, A. Saxena, and R. K. Sharma, “Association of IL-6, IL-10, and TNF-α gene polymorphism with malnutrition inflammation syndrome and survival among end stage renal disease patients,” Journal of Interferon & Cytokine Research, vol. 33, no. 7, pp. 384–391, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Roncero-Ramos, O. A. Rangel-Zuñiga, J. Lopez-Moreno et al., “Mediterranean diet, glucose homeostasis, and inflammasome genetic variants: the CORDIOPREV study,” Molecular Nutrition & Food Research, vol. 62, no. 9, article 1700960, 2018. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ketteler, G. A. Block, P. Evenepoel et al., “Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters,” Kidney International, vol. 92, no. 1, pp. 26–36, 2017. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mihai, E. Codrici, I. D. Popescu et al., “Inflammation and chronic kidney disease: current approaches and recent advances,” in Chronic Kidney Disease, T. Rath, Ed., IntechOpen, Rijeka, Croatia, 2018. View at Google Scholar
  14. A. Ramezani and D. S. Raj, “The gut microbiome, kidney disease, and targeted interventions,” Journal of the American Society of Nephrology, vol. 25, no. 4, pp. 657–670, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Sabatino, G. Regolisti, I. Brusasco, A. Cabassi, S. Morabito, and E. Fiaccadori, “Alterations of intestinal barrier and microbiota in chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 30, no. 6, pp. 924–933, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. S. T. McSorley, D. H. Black, P. G. Horgan, and D. C. McMillan, “The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer,” Clinical Nutrition, vol. 37, no. 4, pp. 1279–1285, 2018. View at Publisher · View at Google Scholar · View at Scopus
  17. C. P. Zambirinis, S. Pushalkar, D. Saxena, and G. Miller, “Pancreatic cancer, inflammation, and microbiome,” Cancer Journal, vol. 20, no. 3, pp. 195–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Bhatelia, K. Singh, and R. Singh, “TLRs: linking inflammation and breast cancer,” Cellular Signalling, vol. 26, no. 11, pp. 2350–2357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. A. G. Kuang, J. C. Nickel, G. L. Andriole, R. Castro-Santamaria, S. J. Freedland, and D. M. Moreira, “Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy,” BJU International, 2018. View at Publisher · View at Google Scholar
  20. Y. Gao, H. Zhang, Y. Li, D. Wang, Y. Ma, and Q. Chen, “Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer,” Clinica Chimica Acta, vol. 484, pp. 272–277, 2018. View at Publisher · View at Google Scholar · View at Scopus
  21. J. N. McAlpine, S. Lisonkova, K. S. Joseph, and P. F. McComb, “Pelvic inflammation and the pathogenesis of ovarian cancer: a cohort study,” International Journal of Gynecological Cancer, vol. 24, no. 8, pp. 1406–1413, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. L. Sowers, K. M. Johnson, C. Conrad, J. T. Patterson, and L. C. Sowers, “The role of inflammation in brain cancer,” Advances in Experimental Medicine and Biology, vol. 816, pp. 75–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Fox, M. Hudson, C. Brown et al., “Markers of systemic inflammation predict survival in patients with advanced renal cell cancer,” British Journal of Cancer, vol. 109, no. 1, pp. 147–153, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. R. Sekar, D. Patil, Y. Baum et al., “A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma,” Asian Journal of Urology, vol. 4, no. 4, pp. 230–238, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Qayyum, P. A. McArdle, G. W. Lamb et al., “Prospective study of the role of inflammation in renal cancer,” Urologia Internationalis, vol. 88, no. 3, pp. 277–281, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. R. de Vivar Chevez, J. Finke, and R. Bukowski, “The role of inflammation in kidney cancer,” Advances in Experimental Medicine and Biology, vol. 816, pp. 197–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. L. W. Henderson, K. M. Koch, C. A. Dinarello, and S. Shaldon, “Hemodialysis hypotension: the interleukin hypothesis,” Blood Purification, vol. 1, no. 1, pp. 3–8, 1983. View at Publisher · View at Google Scholar · View at Scopus
  28. O. M. Akchurin and F. Kaskel, “Update on inflammation in chronic kidney disease,” Blood Purification, vol. 39, no. 1-3, pp. 84–92, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Damkjær, M. Vafaee, M. L. Møller et al., “Renal cortical and medullary blood flow responses to altered NO availability in humans,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 299, no. 6, pp. R1449–R1455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Qian, “Inflammation: a key contributor to the genesis and progression of chronic kidney disease,” Contributions to Nephrology, vol. 191, pp. 72–83, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Ruiz, P. E. Pergola, R. A. Zager, and N. D. Vaziri, “Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease,” Kidney International, vol. 83, no. 6, pp. 1029–1041, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. R. L. Amdur, H. I. Feldman, J. Gupta et al., “Inflammation and progression of CKD: the CRIC study,” Clinical journal of the American Society of Nephrology, vol. 11, no. 9, pp. 1546–1556, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. J. P. Kooman, M. J. Dekker, L. A. Usvyat et al., “Inflammation and premature aging in advanced chronic kidney disease,” American Journal of Physiology-Renal Physiology, vol. 313, no. 4, pp. F938–F950, 2017. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Cafiero, M. Gigante, G. Brunetti et al., “Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems,” Nephrology Dialysis Transplantation, vol. 33, no. 1, pp. 65–75, 2018. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Dungey, K. L. Hull, A. C. Smith, J. O. Burton, and N. C. Bishop, “Inflammatory factors and exercise in chronic kidney disease,” International Journal of Endocrinology, vol. 2013, Article ID 569831, 12 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Martinon, K. Burns, and J. Tschopp, “The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β,” Molecular Cell, vol. 10, no. 2, pp. 417–426, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Kumar, T. Kawai, and S. Akira, “Pathogen recognition by the innate immune system,” International Reviews of Immunology, vol. 30, no. 1, pp. 16–34, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Jin, A. Perry, J. Jiang et al., “Structures of the HIN domain: DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor,” Immunity, vol. 36, no. 4, pp. 561–571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. O. Takeuchi and S. Akira, “Pattern recognition receptors and inflammation,” Cell, vol. 140, no. 6, pp. 805–820, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. M. Turner, N. Arulkumaran, M. Singer, R. J. Unwin, and F. W. K. Tam, “Is the inflammasome a potential therapeutic target in renal disease?” BMC Nephrology, vol. 15, no. 1, p. 21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. H. L. Hutton, J. D. Ooi, S. R. Holdsworth, and A. R. Kitching, “The NLRP3 inflammasome in kidney disease and autoimmunity,” Nephrology, vol. 21, no. 9, pp. 736–744, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Martinon, “Signaling by ROS drives inflammasome activation,” European Journal of Immunology, vol. 40, no. 3, pp. 616–619, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. N. Darisipudi and F. Knauf, “An update on the role of the inflammasomes in the pathogenesis of kidney diseases,” Pediatric Nephrology, vol. 31, no. 4, pp. 535–544, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. T. S. Puri, M. I. Shakaib, A. Chang et al., “Chronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic background,” American Journal of Physiology-Renal Physiology, vol. 298, no. 4, pp. F1024–F1032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Vilaysane, J. Chun, M. E. Seamone et al., “The NLRP3 inflammasome promotes renal inflammation and contributes to CKD,” Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1732–1744, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. W. P. Pulskens, L. M. Butter, G. J. Teske et al., “Nlrp3 prevents early renal interstitial edema and vascular permeability in unilateral ureteral obstruction,” PLoS One, vol. 9, no. 1, article e85775, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Chang, K. Ko, and M. R. Clark, “The emerging role of the inflammasome in kidney diseases,” Current Opinion in Nephrology and Hypertension, vol. 23, no. 3, pp. 204–210, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Fukami, S. Yamagishi, H. Adachi et al., “High white blood cell count and low estimated glomerular filtration rate are independently associated with serum level of monocyte chemoattractant protein-1 in a general population,” Clinical Cardiology, vol. 34, no. 3, pp. 189–194, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. K. Nicholson, E. Holmes, J. Kinross et al., “Host-gut microbiota metabolic interactions,” Science, vol. 336, no. 6086, pp. 1262–1267, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. The Human Microbiome Project Consortium, “A framework for human microbiome research,” Nature, vol. 486, no. 7402, pp. 215–221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Hattori, “Advanced technologies for the human gut microbiome analysis,” Japanese Journal of Clinical Immunology, vol. 37, no. 5, pp. 412–422, 2014. View at Publisher · View at Google Scholar
  52. W. L. Lau, J. Savoj, M. B. Nakata, and N. D. Vaziri, “Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins,” Clinical Science, vol. 132, no. 5, pp. 509–522, 2018. View at Publisher · View at Google Scholar · View at Scopus
  53. B. K. I. Meijers and P. Evenepoel, “The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression,” Nephrology Dialysis Transplantation, vol. 26, no. 3, pp. 759–761, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Al Khodor and I. F. Shatat, “Gut microbiome and kidney disease: a bidirectional relationship,” Pediatric Nephrology, vol. 32, no. 6, pp. 921–931, 2017. View at Publisher · View at Google Scholar · View at Scopus
  55. B. Meijers, F. Jouret, and P. Evenepoel, “Linking gut microbiota to cardiovascular disease and hypertension: lessons from chronic kidney disease,” Pharmacological Research, vol. 133, pp. 101–107, 2018. View at Publisher · View at Google Scholar · View at Scopus
  56. W. Huang, L. Zhou, H. Guo, Y. Xu, and Y. Xu, “The role of short-chain fatty acids in kidney injury induced by gut-derived inflammatory response,” Metabolism, vol. 68, pp. 20–30, 2017. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Evenepoel, R. Poesen, and B. Meijers, “The gut-kidney axis,” Pediatric Nephrology, vol. 32, no. 11, pp. 2005–2014, 2017. View at Publisher · View at Google Scholar · View at Scopus
  58. W. L. Lau, K. Kalantar-Zadeh, and N. D. Vaziri, “The gut as a source of inflammation in chronic kidney disease,” Nephron, vol. 130, no. 2, pp. 92–98, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. E. Montemurno, C. Cosola, G. Dalfino et al., “What would you like to eat, Mr CKD microbiota? A Mediterranean diet, please!,” Kidney and Blood Pressure Research, vol. 39, no. 2-3, pp. 114–123, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. D. F. Romagnolo and O. I. Selmin, “Mediterranean diet and prevention of chronic diseases,” Nutrition Today, vol. 52, no. 5, pp. 208–222, 2017. View at Publisher · View at Google Scholar · View at Scopus
  61. X. Huang, J. J. Jimenez-Moleon, B. Lindholm et al., “Mediterranean diet, kidney function, and mortality in men with CKD,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 9, pp. 1548–1555, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Cupisti, C. D'Alessandro, L. Gesualdo et al., “Non-traditional aspects of renal diets: focus on fiber, alkali and vitamin K1 intake,” Nutrients, vol. 9, no. 5, 2017. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Chauveau, C. Combe, D. Fouque, and M. Aparicio, “Vegetarianism: advantages and drawbacks in patients with chronic kidney diseases,” Journal of Renal Nutrition, vol. 23, no. 6, pp. 399–405, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Asghari, E. Yuzbashian, P. Mirmiran, and F. Azizi, “The association between Dietary Approaches to Stop Hypertension and incidence of chronic kidney disease in adults: the Tehran Lipid and Glucose Study,” Nephrology Dialysis Transplantation, vol. 32, Supplement 2, pp. ii224–ii230, 2017. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Shi, A. W. Taylor, M. Riley, J. Byles, J. Liu, and M. Noakes, “Association between dietary patterns, cadmium intake and chronic kidney disease among adults,” Clinical Nutrition, vol. 37, no. 1, pp. 276–284, 2018. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Lin, T. T. Fung, F. B. Hu, and G. C. Curhan, “Association of dietary patterns with albuminuria and kidney function decline in older white women: a subgroup analysis from the Nurses' Health Study,” American Journal of Kidney Diseases, vol. 57, no. 2, pp. 245–254, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. O. M. Gutiérrez, P. Muntner, D. V. Rizk et al., “Dietary patterns and risk of death and progression to ESRD in individuals with CKD: a cohort study,” American Journal of Kidney Diseases, vol. 64, no. 2, pp. 204–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Banerjee, D. C. Crews, D. E. Wesson et al., “High dietary acid load predicts ESRD among adults with CKD,” Journal of the American Society of Nephrology, vol. 26, no. 7, pp. 1693–1700, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. C. C. Tyson, P. H. Lin, L. Corsino et al., “Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a pilot feeding study,” Clinical Kidney Journal, vol. 9, no. 4, pp. 592–598, 2016. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Rysz, B. Franczyk, A. Ciałkowska-Rysz, and A. Gluba-Brzózka, “The effect of diet on the survival of patients with chronic kidney disease,” Nutrients, vol. 9, no. 5, 2017. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Iwashita, M. Ohya, M. Yashiro et al., “Dietary changes involving Bifidobacterium longum and other nutrients delays chronic kidney disease progression,” American Journal of Nephrology, vol. 47, no. 5, pp. 325–332, 2018. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Ranganathan, P. Ranganathan, E. A. Friedman et al., “Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease,” Advances in Therapy, vol. 27, no. 9, pp. 634–647, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Nallu, S. Sharma, A. Ramezani, J. Muralidharan, and D. Raj, “Gut microbiome in chronic kidney disease: challenges and opportunities,” Translational Research, vol. 179, pp. 24–37, 2017. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Hasegawa, T. M. Jao, and R. Inagi, “Dietary metabolites and chronic kidney disease,” Nutrients, vol. 9, no. 4, 2017. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Rossi, D. W. Johnson, M. Morrison et al., “Synbiotics easing renal failure by improving gut microbiology (SYNERGY): a randomized trial,” Clinical Journal of the American Society of Nephrology, vol. 11, no. 2, pp. 223–231, 2016. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Rossi, K. Klein, D. W. Johnson, and K. L. Campbell, “Pre-, pro-, and synbiotics: do they have a role in reducing uremic toxins? A systematic review and meta-analysis,” International Journal of Nephrology, vol. 2012, 20 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. M. L. Simenhoff, S. R. Dunn, G. P. Zollner et al., “Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus,” Mineral and Electrolyte Metabolism, vol. 22, no. 1-3, pp. 92–96, 1996. View at Google Scholar
  78. N. Ranganathan, B. Patel, P. Ranganathan et al., “Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats,” TheScientificWorldJOURNAL, vol. 5, pp. 652–660, 2005. View at Publisher · View at Google Scholar
  79. N. Ranganathan, B. G. Patel, P. Ranganathan et al., “In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease,” ASAIO Journal, vol. 52, no. 1, pp. 70–79, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Niwa, “Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120,” Therapeutic Apheresis and Dialysis, vol. 15, no. 2, pp. 120–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. F. Takayama, K. Taki, and T. Niwa, “Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis,” American Journal of Kidney Diseases, vol. 41, no. 3, pp. S142–S145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. K. Taki, F. Takayama, and T. Niwa, “Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients,” Journal of Renal Nutrition, vol. 15, no. 1, pp. 77–80, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. B. K. I. Meijers, V. de Preter, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel, “p-cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin,” Nephrology Dialysis Transplantation, vol. 25, no. 1, pp. 219–224, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. T. L. Sirich, N. S. Plummer, C. D. Gardner, T. H. Hostetter, and T. W. Meyer, “Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 9, pp. 1603–1610, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. I. Nakabayashi, M. Nakamura, K. Kawakami et al., “Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study,” Nephrology Dialysis Transplantation, vol. 26, no. 3, pp. 1094–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. A. Fouad and C. Aanei, “Revisiting the hallmarks of cancer,” American Journal of Cancer Research, vol. 7, no. 5, pp. 1016–1036, 2017. View at Google Scholar
  88. F. Balkwill and A. Mantovani, “Inflammation and cancer: back to Virchow?” Lancet, vol. 357, no. 9255, pp. 539–545, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Neagu, C. Caruntu, C. Constantin et al., “Chemically induced skin carcinogenesis: updates in experimental models (review),” Oncology Reports, vol. 35, no. 5, pp. 2516–2528, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. C. Pistol-Tanase, E. Raducan, S. O. Dima et al., “Assessment of soluble angiogenic markers in pancreatic cancer,” Biomarkers in Medicine, vol. 2, no. 5, pp. 447–455, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Korniluk, O. Koper, H. Kemona, and V. Dymicka-Piekarska, “From inflammation to cancer,” Irish Journal of Medical Science, vol. 186, no. 1, pp. 57–62, 2017. View at Publisher · View at Google Scholar · View at Scopus
  92. N. V. Apanovich, M. V. Peters, P. V. Apanovich et al., “Expression profiles of genes-potential therapy targets-and their relationship to survival in renal cell carcinoma,” Doklady Biochemistry and Biophysics, vol. 478, no. 1, pp. 14–17, 2018. View at Publisher · View at Google Scholar · View at Scopus
  93. C. P. Tanase, M. Neagu, and R. Albulescu, “Key signaling molecules in pituitary tumors,” Expert Review of Molecular Diagnostics, vol. 9, no. 8, pp. 859–877, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. A. Mantovani, C. Garlanda, and P. Allavena, “Molecular pathways and targets in cancer-related inflammation,” Annals of Medicine, vol. 42, no. 3, pp. 161–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Del Prete, P. Allavena, G. Santoro, R. Fumarulo, M. M. Corsi, and A. Mantovani, “Molecular pathways in cancer-related inflammation,” Biochemia Medica, vol. 21, no. 3, pp. 264–275, 2011. View at Publisher · View at Google Scholar
  96. Y. Xia, S. Shen, and I. M. Verma, “NF-κB, an active player in human cancers,” Cancer Immunology Research, vol. 2, no. 9, pp. 823–830, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. L. M. Staudt, “Oncogenic activation of NF-kappaB,” Cold Spring Harbor Perspectives in Biology, vol. 2, no. 6, article a000109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. J. A. DiDonato, F. Mercurio, and M. Karin, “NF-κB and the link between inflammation and cancer,” Immunological Reviews, vol. 246, no. 1, pp. 379–400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Kaltschmidt, J. F. W. Greiner, H. M. Kadhim, and C. Kaltschmidt, “Subunit-specific role of NF-κB in cancer,” Biomedicine, vol. 6, no. 2, 2018. View at Publisher · View at Google Scholar
  100. S. M. Crusz and F. R. Balkwill, “Inflammation and cancer: advances and new agents,” Nature Reviews Clinical Oncology, vol. 12, no. 10, pp. 584–596, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Liu, H. Wu, D. Shangguan et al., “Immunomodulatory therapies for renal cell carcinoma,” Protein & Peptide Letters, vol. 25, 2018. View at Publisher · View at Google Scholar
  102. P. Russo, “End stage and chronic kidney disease: associations with renal cancer,” Frontiers in Oncology, vol. 2, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. Neuzillet, X. Tillou, R. Mathieu et al., “Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population,” European Urology, vol. 60, no. 2, pp. 366–373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Demirjian, B. R. Lane, I. H. Derweesh, T. Takagi, A. Fergany, and S. C. Campbell, “Chronic kidney disease due to surgical removal of nephrons: relative rates of progression and survival,” The Journal of Urology, vol. 192, no. 4, pp. 1057–1063, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. S. Dey, Z. Hamilton, S. L. Noyes et al., “Chronic kidney disease is more common in locally advanced renal cell carcinoma,” Urology, vol. 105, pp. 101–107, 2017. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Ahn, R. J. Ellis, V. M. White et al., “Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: an Australian population-based analysis,” Journal of Surgical Oncology, vol. 117, no. 7, pp. 1597–1610, 2018. View at Publisher · View at Google Scholar
  107. S. A. Poon, J. L. Silberstein, L. Y. Chen, B. Ehdaie, P. H. Kim, and P. Russo, “Trends in partial and radical nephrectomy: an analysis of case logs from certifying urologists,” The Journal of Urology, vol. 190, no. 2, pp. 464–469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Izzedine and M. A. Perazella, “Onco-nephrology: an appraisal of the cancer and chronic kidney disease links,” Nephrology Dialysis Transplantation, vol. 30, no. 12, pp. 1979–1988, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. K. K. Brodaczewska, C. Szczylik, and C. Kieda, “Immune consequences of anti-angiogenic therapy in renal cell carcinoma,” Contemporary Oncology, vol. 2018, no. 1, pp. 14–22, 2018. View at Publisher · View at Google Scholar
  110. G. Remuzzi and T. Bertani, “Pathophysiology of progressive nephropathies,” The New England Journal of Medicine, vol. 339, no. 20, pp. 1448–1456, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. E. R. Smith, D. Lee, M. M. Cai et al., “Urinary neutrophil gelatinase-associated lipocalin may aid prediction of renal decline in patients with non-proteinuric stages 3 and 4 chronic kidney disease (CKD),” Nephrology Dialysis Transplantation, vol. 28, no. 6, pp. 1569–1579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. T. Gohda, M. A. Niewczas, L. H. Ficociello et al., “Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes,” Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 516–524, 2012. View at Publisher · View at Google Scholar · View at Scopus
  113. K. D. Liu, W. Yang, A. H. Anderson et al., “Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease,” Kidney International, vol. 83, no. 5, pp. 909–901414, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. M. A. Niewczas, T. Gohda, J. Skupien et al., “Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes,” Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 507–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. S. S. Hayek, S. Sever, Y. A. Ko et al., “Soluble urokinase receptor and chronic kidney disease,” The New England Journal of Medicine, vol. 373, no. 20, pp. 1916–1925, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Bazeley, B. Bieber, Y. Li et al., “C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 10, pp. 2452–2461, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Gupta, N. Mitra, P. A. Kanetsky et al., “Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 12, pp. 1938–1946, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. P.-O. Sundin, R. Udumyan, P. Sjöström, and S. Montgomery, “Predictors in adolescence of ESRD in middle-aged men,” American Journal of Kidney Diseases, vol. 64, no. 5, pp. 723–729, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. M. K. Fallahzadeh, J. Roozbeh, B. Geramizadeh, and M. R. Namazi, “Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications,” Nephrology Dialysis Transplantation, vol. 26, no. 10, pp. 3338–3344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. A. B. Sanz, M. C. Izquierdo, M. D. Sanchez-Nino et al., “TWEAK and the progression of renal disease: clinical translation,” Nephrology Dialysis Transplantation, vol. 29, Supplement 1, pp. i54–i62, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. Á. C. Ucero, S. Berzal, C. Ocaña-Salceda et al., “A polymeric nanomedicine diminishes inflammatory events in renal tubular cells,” PLoS One, vol. 8, no. 1, article e51992, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. S. D. Cohen, T. M. Phillips, P. Khetpal, and P. L. Kimmel, “Cytokine patterns and survival in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 25, no. 4, pp. 1239–1243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Shankar, S. Syamala, J. Xiao, and P. Muntner, “Relationship between plasma leptin level and chronic kidney disease,” International Journal of Nephrology, vol. 2012, Article ID 269532, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. P. M. C. S. De Silva, K. S. M. Abdul, E. M. D. V. Eakanayake et al., “Urinary biomarkers KIM-1 and NGAL for detection of chronic kidney disease of uncertain etiology (CKDu) among agricultural communities in Sri Lanka,” PLOS Neglected Tropical Diseases, vol. 10, no. 9, article e0004979, 2016. View at Publisher · View at Google Scholar · View at Scopus
  125. B. D. Humphreys, F. Xu, V. Sabbisetti et al., “Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis,” Journal of Clinical Investigation, vol. 123, no. 9, pp. 4023–4035, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Sayanthooran, D. N. Magana-Arachchi, L. Gunerathne, and T. Abeysekera, “Potential diagnostic biomarkers for chronic kidney disease of unknown etiology (CKDu) in Sri Lanka: a pilot study,” BMC Nephrology, vol. 18, no. 1, p. 31, 2017. View at Publisher · View at Google Scholar · View at Scopus
  127. C. R. Parikh, H. Thiessen-Philbrook, A. X. Garg et al., “Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery,” Clinical Journal of the American Society of Nephrology, vol. 8, no. 7, pp. 1079–1088, 2013. View at Publisher · View at Google Scholar · View at Scopus
  128. W. K. Han, V. Bailly, R. Abichandani, R. Thadhani, and J. V. Bonventre, “Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury,” Kidney International, vol. 62, no. 1, pp. 237–244, 2002. View at Publisher · View at Google Scholar · View at Scopus
  129. T. Ichimura, J. V. Bonventre, V. Bailly et al., “Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury,” The Journal of Biological Chemistry, vol. 273, no. 7, pp. 4135–4142, 1998. View at Publisher · View at Google Scholar · View at Scopus
  130. H. I. Brunner, M. Mueller, C. Rutherford et al., “Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 54, no. 8, pp. 2577–2584, 2006. View at Publisher · View at Google Scholar · View at Scopus
  131. H. Trachtman, E. Christen, A. Cnaan et al., “Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury,” Pediatric Nephrology, vol. 21, no. 7, pp. 989–994, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. T. Kuwabara, K. Mori, M. Mukoyama et al., “Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons,” Kidney International, vol. 75, no. 3, pp. 285–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. Y.-K. Tsau and C.-H. Chen, “Urinary epidermal growth factor excretion in children with chronic renal failure,” American Journal of Nephrology, vol. 19, no. 3, pp. 400–404, 1999. View at Publisher · View at Google Scholar · View at Scopus
  134. W. Ju, V. Nair, S. Smith et al., “Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker,” Science Translational Medicine, vol. 7, no. 316, article 316ra193, 2015. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Korzeniecka-Kozerska, A. Wasilewska, E. Tenderenda, A. Sulik, and K. Cybulski, “Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children,” Disease Markers, vol. 34, no. 5, 362 pages, 2013. View at Publisher · View at Google Scholar
  136. K. Musial and D. Zwolinska, “Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment,” Cell Stress and Chaperones, vol. 16, no. 1, pp. 97–103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  137. T. W. Hsu, K. L. Kuo, S. C. Hung, P. H. Huang, J. W. Chen, and D. C. Tarng, “Progression of kidney disease in non-diabetic patients with coronary artery disease: predictive role of circulating matrix metalloproteinase-2, -3, and -9,” PLoS One, vol. 8, no. 7, article e70132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. H. R. Vianna, C. M. B. M. Soares, K. D. Silveira et al., “Cytokines in chronic kidney disease: potential link of MCP-1 and dyslipidemia in glomerular diseases,” Pediatric Nephrology, vol. 28, no. 3, pp. 463–469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. R. Camilla, S. Brachemi, V. Pichette et al., “Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease,” Journal of Nephrology, vol. 24, no. 1, pp. 60–67, 2011. View at Google Scholar
  140. K. Musiał, A. Bargenda, D. Drożdż, and D. Zwolińska, “New markers of inflammation and tubular damage in children with chronic kidney disease,” Disease Markers, vol. 2017, Article ID 9389432, 5 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  141. A. Levin, M. Tonelli, J. Bonventre et al., “Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy,” Lancet, vol. 390, no. 10105, pp. 1888–1917, 2017. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Pejchinovski and H. Mischak, “Clinical proteomics in kidney disease: from discovery to clinical application,” Prilozi, vol. 38, no. 3, pp. 39–54, 2017. View at Publisher · View at Google Scholar
  143. S. Mihai, E. Codrici, I. D. Popescu et al., “Proteomic biomarkers panel: new insights in chronic kidney disease,” Disease Markers, vol. 2016, Article ID 3185232, 11 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  144. I. D. Popescu, R. Albulescu, E. L. Raducan, A. N. Dinischiotu, and C. R. Tanase, “Applications of SELDI-TOF technology in cancer biomarkers discovery,” Romanian Biotechnological Letters, vol. 15, pp. 5654–5667, 2010. View at Google Scholar
  145. J. C. He, P. Y. Chuang, A. Ma'ayan, and R. Iyengar, “Systems biology of kidney diseases,” Kidney International, vol. 81, no. 1, pp. 22–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. C. P. Tanase, R. Albulescu, and M. Neagu, “Application of 3D hydrogel microarrays in molecular diagnostics: advantages and limitations,” Expert Review of Molecular Diagnostics, vol. 11, no. 5, pp. 461–464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  147. A. M. Tsatsakis, D. Kouretas, M. N. Tzatzarakis et al., “Simulating real-life exposures to uncover possible risks to human health: a proposed consensus for a novel methodological approach,” Human & Experimental Toxicology, vol. 36, no. 6, pp. 554–564, 2017. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Smith, V. L'Imperio, G. De Sio et al., “α-1-Antitrypsin detected by MALDI imaging in the study of glomerulonephritis: its relevance in chronic kidney disease progression,” Proteomics, vol. 16, no. 11-12, pp. 1759–1766, 2016. View at Publisher · View at Google Scholar · View at Scopus
  149. J. Siwy, P. Zürbig, A. Argiles et al., “Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis,” Nephrology Dialysis Transplantation, vol. 32, no. 12, pp. 2079–2089, 2017. View at Publisher · View at Google Scholar · View at Scopus
  150. J. P. Schanstra, P. Zurbig, A. Alkhalaf et al., “Diagnosis and prediction of CKD progression by assessment of urinary peptides,” Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1999–2010, 2015. View at Publisher · View at Google Scholar · View at Scopus
  151. D. M. Good, P. Zürbig, À. Argilés et al., “Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease,” Molecular & Cellular Proteomics, vol. 9, no. 11, pp. 2424–2437, 2010. View at Publisher · View at Google Scholar · View at Scopus
  152. C. Pontillo, Z. Y. Zhang, J. P. Schanstra et al., “Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker,” Kidney International Reports, vol. 2, no. 6, pp. 1066–1075, 2017. View at Publisher · View at Google Scholar · View at Scopus
  153. E. Subasi, M. M. Subasi, P. L. Hammer, J. Roboz, V. Anbalagan, and M. S. Lipkowitz, “A classification model to predict the rate of decline of kidney function,” Frontiers in Medicine, vol. 4, p. 97, 2017. View at Publisher · View at Google Scholar
  154. E. Nkuipou-Kenfack, P. Zürbig, and H. Mischak, “The long path towards implementation of clinical proteomics: exemplified based on CKD273,” PROTEOMICS - Clinical Applications, vol. 11, no. 5-6, article 1600104,, 2017. View at Publisher · View at Google Scholar · View at Scopus
  155. P. Moulos, J. Klein, S. Jupp, R. Stevens, J. L. Bascands, and J. P. Schanstra, “The KUPNetViz: a biological network viewer for multiple -omics datasets in kidney diseases,” BMC Bioinformatics, vol. 14, no. 1, p. 235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. M. Fernandes and H. Husi, “Establishment of a integrative multi-omics expression database CKDdb in the context of chronic kidney disease (CKD),” Scientific Reports, vol. 7, no. 1, p. 40367, 2017. View at Publisher · View at Google Scholar · View at Scopus
  157. M. H. Hanna, A. Dalla Gassa, G. Mayer et al., “The nephrologist of tomorrow: towards a kidney-omic future,” Pediatric Nephrology, vol. 32, no. 3, pp. 393–404, 2017. View at Publisher · View at Google Scholar · View at Scopus